SuperworthIQVIA EPS IQV
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- $8.06
- Latest quarter, Q2 FY26
- $1.53
- −1% on a year earlier
- Fiscal year 2025
- $7.86
- +5% on the year before
IQVIA's earnings per share was $8.06 over the twelve months to Jun 30, 2026, up 17% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.53, down 1% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 41% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $7.86 | +5% |
| FY2024 | $7.50 | +3% |
| FY2023 | $7.29 | +28% |
| FY2022 | $5.71 | +15% |
| FY2021 | $4.96 | +247% |
| FY2020 | $1.43 | +47% |
| FY2019 | $0.97 | −22% |
| FY2018 | $1.24 | −79% |
| FY2017 | $5.90 | +87% |
| FY2016 | $3.16 | +3% |
| FY2015 | $3.08 | +13% |
| FY2014 | $2.72 | +55% |
| FY2013 | $1.76 | +17% |
| FY2012 | $1.51 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.53 | −1% | $8.06 | |
| Q1 FY26 | $1.61 | +15% | $8.07 | |
| Q4 FY25 | $2.99 | +24% | $7.86 | |
| Q3 FY25 | $1.93 | +25% | $7.29 | |
| Q2 FY25 | $1.54 | −22% | $6.91 | |
| Q1 FY25 | $1.40 | −10% | $7.34 | |
| Q4 FY24 | $2.42 | −5% | $7.50 | |
| Q3 FY24 | $1.55 | −5% | $7.62 | |
| Q2 FY24 | $1.97 | +24% | $7.70 | |
| Q1 FY24 | $1.56 | +2% | $7.32 | |
| Q4 FY23 | $2.54 | +112% | $7.29 | |
| Q3 FY23 | $1.63 | +9% | $5.95 |
Against its peers
Companies in Medical - Diagnostics & Research nearest IQVIA's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IQVIQVIA | $8.06 | +17% a year |
| WATWaters | $4.01 | −64% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| AAgilent Technologies | $5.09 | +19% a year |
| ILMNIllumina | $5.38 | −32% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| LHLabcorp | $12.09 | +33% a year |
| MEDPMedpace | $17.05 | +27% a year |
| RVTYRevvity | $2.10 | −11% a year |
| DHRDanaher | $5.63 | +20% a year |
| Peer median | $7.52 |
Where IQVIA ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on IQVIA
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.